pipequaline
Sign in to savePipequaline (INN; development code PK-8165) is an anxiolytic drug that was never marketed. It possesses a novel chemical structure that is not closely related to other drugs of this type. The drug has a similar pharmacological profile to the benzodiazepine family of drugs, but with mainly anxiolytic properties and very little sedative, amnestic or anticonvulsant effects, and so is classified as a nonbenzodiazepine anxiolytic.
Research
32 papers- Pipequaline acts as a partial agonist of benzodiazepine receptors: an electrophysiological study in the hippocampus of the rat.Neuropharmacology · 1987
- The effects on memory of pipequaline, alone or in combination with diazepam.Psychopharmacology · 1988
- Pipequaline transport from blood to brain and liver: role of plasma protein-bound drug.The Journal of pharmacy and pharmacology · 1989
- Anxioselective anxiolytics.Journal of medicinal chemistry · 1983
- Binding in vitro of pipequaline (45319 RP) onto plasma proteins and blood cells in man.Biochemical pharmacology · 1987
via PubMed
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Pipequaline (INN; development code PK-8165) is an anxiolytic drug that was never marketed. It possesses a novel chemical structure that is not closely related to other drugs of this type. The drug has a similar pharmacological profile to the benzodiazepine family of drugs, but with mainly anxiolytic properties and very little sedative, amnestic or anticonvulsant effects, and so is classified as a nonbenzodiazepine anxiolytic.
Pipequaline acts as a non-selective GABAA receptor partial agonist. While its profile of anxiolytic effects without sedation would appear to have potential medical applications, pipequaline has never been developed for medical use and is currently only used in scientific research.
Excerpted from Wikipedia’s “pipequaline” article, available under the CC BY-SA 4.0 licence.